Sun gets US FDA nod for eye drug

The company, which also launched ophthalmic division in US, earns about half its consolidated revenue from United States

Sun Pharmaceutical Industries has received US Food and Drug Administration approval for an ophthalmic solution, used for preventing pain and treating inflammation in eye, after cataract surgery. The solution, BromSite, has been developed by InSite Vision, a specialty ophthalmic products firm bought by Sun last year.   

The US FDA approval for the product is positive for Sun Pharma, which earns about half its consolidated revenue from the US.  The firm has identified dermatology and ophthalmics as key  segments to establish branded business in the US.

Read more from our special coverage on "SUN PHARMA"

• Sun Pharma buys Novartis brands for Rs 1,900 cr
• Sun Pharma to sell AstraZenecas diabetes drug in India
• Sun Pharma to sell AstraZenecas diabetes drug in India
• Sun Pharma names Dhoni as Revital H brand ambassador

It is  likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics, in the second half of 2016.

BromSite  is the first non-steroidal anti-inflammatory drug (NSAID) approved by the US FDA to prevent pain and treat inflammation.

According to IMS MAT January 2016, the US NSAID ophthalmic market grew  eight per cent, generating approximately $400 million  in sales and about four million prescriptions, providing an attractive market for Sun Pharma to participate, the company said.

Sun Ophthalmics has crossed a key business milestone through BromSite’s approval.

Sun Ophthalmics targets to provide eye care practitioners products that enhance their practice patterns and treatment options and to deliver those products through its unique, concierge level approach to customer care.

With BromSite’s approval and additional late-stage candidates in its pipeline, Sun Ophthalmics is strongly positioned to offer a range of beneficial products and establish itself as a respected and trusted partner, it said.